Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Twitter icon
Created with Sketch.
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
Duke Capital
FY’24 results: record cashflows
12th Jul 2024
Apax Global Alpha
CM day: further proof of value added by Apax
10th Jul 2024
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
99: Building a medical company without a specialist background | Clare Brenner of Myogenes
Stay up-to-date with the latest research
Sign up to our newsletter
Life Sciences research
genedrive Plc
Life Sciences
Acceleration of news flow expected
28 Oct 2019
Oxford BioMedica
Life Sciences
Demanding second half
16 Oct 2019
Stay up-to-date with the latest research
Sign up to our newsletter
Allergy Therapeutics plc
Life Sciences
Continuing to gain market share
26 Sep 2019
Shield Therapeutics Plc
Life Sciences
FDA approval ushers in a new era for Shield
02 Sep 2019
Advanced Oncotherapy
Life Sciences
Nearing the end-goal
By
Dr Martin Hall
08 Aug 2019
Shield Therapeutics Plc
Life Sciences
FDA approval opens door to major US opportunity
05 Aug 2019
Redx Pharma
Life Sciences
Pan-RAF agreement strengthens balance sheet
18 Jul 2019
genedrive Plc
Life Sciences
Hepatitis C market frustrations
18 Jul 2019
Redx Pharma
Life Sciences
Phase I trial resumed
10 Jul 2019
Allergy Therapeutics plc
Life Sciences
Successful legal outcome removes uncertainty
01 Jul 2019
Oxford BioMedica
Life Sciences
Eying up long-term value
01 Jul 2019
Prev
1
...
7
8
9
10
11
...
21
Next